Purpose A prospective randomized trial in small-cell lung cancer (SCLC) was performed to
determine if intensification of the platinum dose by giving cisplatin and carboplatin in …

This is a comment on" Superiority of high-dose platinum (cisplatin and carboplatin)
compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma …

PURPOSE The trial was undertaken to determine (1) the relative efficacy/toxicity of two
commonly used combination chemotherapy regimens in patients with extensive small-cell …

Carboplatin is one of the most active agents in untreated small cell lung cancer (SCLC)(11%
complete response [CR], 59% CR plus partial response [PR]). Combination …

Objective This retrospective analysis evaluates the clinical outcomes of extensive-stage
small cell lung cancer (SCLC) patients who received second-line chemotherapy after …

Background A phase II randomised trial was performed with patients with SCLC to
determine if the addition of carboplatin to cisplatin–etoposide might improve the response …

PURPOSE: The combination of cisplatin, etoposide, and paclitaxel was studied in patients
with extensive small-cell lung cancer in a phase I component followed by a phase II trial to …

We have treated sixty-two patients (21 with limited disease, 41 with extensive disease), on
an outpatient-basis schedule of six drugs administered weekly for twelve weeks …

Chemotherapy is the backbone of small-cell lung cancer therapy. However, optimal drug
combinations and schedules remain to be defined and there is hitherto no world-wide …

Purpose: to compare standard and alternating administration of chemotherapy combinations
in small cell lung cancer (SCLC) patients. Material and methods: in a multicenter clinical …